1.65
+0.01
(0.61%)
Real-time:
2:20PM EDT
NYSEMKT
real-time data -
Disclaimer
Currency in USD
| Range | 1.63 - 1.71 |
| 52 week | 0.98 - 2.05 |
| Open | 1.65 |
| Vol / Avg. | 93,626.00/227,970.00 |
| Mkt cap | 79.80M |
| P/E | - |
| Div/yield | - |
| EPS | -0.10 |
| Shares | 48.37M |
| Beta | 1.63 |
| Inst. own | 34% |
Events
Jul 9, 2013
PharmAthene, Inc. at JMP Securities Healthcare Conference
Jun 11, 2013
PharmAthene, Inc. Annual Shareholder Meeting
- 10:00AM EDT -
May 8, 2013
Q1 2013 PharmAthene, Inc. Earnings Conference Call -
May 6, 2013
Q1 2013 PharmAthene, Inc. Earnings Release
Mar 13, 2013
Q4 2012 PharmAthene, Inc. Earnings Conference Call -
|
More events from DailyFinance »
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | -21.11% | -19.54% |
| Operating margin | -23.73% | -24.89% |
| EBITD margin | - | -23.68% |
| Return on average assets | -22.07% | -21.61% |
| Return on average equity | -42.05% | -35.75% |
| Employees | 57 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite #450, One Park Place
ANNAPOLIS, MD 21401
United States - Map
+1-410-2692600 (Phone)
+1-410-2692601 (Fax)
ANNAPOLIS, MD 21401
United States - Map
+1-410-2692600 (Phone)
+1-410-2692601 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Develops treatments of diseases associated with biological warfare threats. The Company operates as a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats. PhamAthene's product "Valortim" is a human monoclonal antibody designed to protect against inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium.
Officers and directors
| Mitchel B. Sayare Ph.D. | Independent Chairman of the Board | |
| Eric I. Richman | President, Chief Executive Officer, Director | |
| Linda L. Chang | Chief Financial Officer, Senior Vice President | |
| Jordan P. Karp Esq. | Senior Vice President, General Counsel, Corporate Secretary | |
| Francesca M. Cook | Senior Vice President - Policy and Government Affairs | |
| Wayne Morges Ph.D. | Senior Vice President - Regulatory Affairs and Quality | |
| Elliott Y. Elliott Ph.D. | Chief Scientific Officer | |
| John M. Gill | Independent Director | |
| Brian A. Markison | Independent Director | |
| Joel W. McCleary | Independent Director |